Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 658-667

  Von Pawel, Joachim ^a   Schiller, Joan H ^a   Shepherd, Frances A ^a   Fields, Scott Z ^a   Kleisbauer, J P ^a   Chrysson, Nick G ^a   Stewart, David J ^a   Clark, Peter I ^a   Palmer, Martin C ^a   Depierre, Alain ^a   Carmichael, James ^a   Krebs, Jacqueline B ^a   Ross, Graham ^a   Lane, Stephen R ^a   Gralla, Richard ^a  

^a HÔPITAL SAINT JACQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA;

EID: 0033044111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.658     Document Type: Article

References (38)

1. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase III trial of Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
2. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
3. Sculier JP, Klastersky J, Libert P, et al: A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 6:110-118, 1990
4. Shepherd FA, Evans WK, MacCormick R, et al: Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer. Cancer Treat Rep 71:941-944, 1987
5. American Cancer Society: Cancer Facts & Figures. Atlanta, GA, American Cancer Society, Inc, 1997
6. Minna JD: Neoplasms of the lung, in Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 1994, pp 1221-1229
7. National Cancer Institute: Physician's Data Query Cancer Information Summaries: Small-cell lung cancer - prognosis [online]. Updated May 1996. Available at: http://cancernet.nci.nih.gov/clinpdq/soa/ Small_cell_lung_cancer_Physician.html#1
8. National Cancer Institute: Physician's Data Query Cancer Information Summaries: Small-cell lung cancer - limited stage small-cell lung cancer [online]. Updated May 1996. Available at: http://cancernet.nci. nih.gov/clinpdq/soa/Small_cell_lung_cancer_Physician.html#7
9. National Cancer Institute: Physician's Data Query Cancer Information Summaries: Small-cell lung cancer - extensive stage small-cell lung cancer [online]. Updated May 1996. Available at: http://cancernet.nci.nih.gov/clinpdq/soa/Small_cell_lung_cancer_ Physician.html#8
10. Ihde DC, Pass HI, Glatstein EJ: Small-cell lung cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott-Raven, 1993, p 749
11. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
12. Depierre A, von Pawel J, Hans K, et al: Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter Phase II study. Lung Cancer 18:35, 1997 (abstr 126)
13. Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A Phase II study. Ann Oncol 7:107, 1996 (abstr 513)
14. Eckardt J, Depierre A, Ardizzoni A, et al: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol, 16:452a, 1997 (abstr 1624)
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
16. National Cancer Institute: Guidelines for Reporting Adverse Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
17. Hansen HH: Management of small-cell lung cancer. Lancet 339:846-849, 1992
18. Albain KS, Crowley JJ, Hutchins L, et al: Predictors of survival following relapse or progression of small cell lung cancer. Cancer 72:1184-1191, 1993
19. Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase poison topotecan. J Clin Oncol 14:2785-2790, 1996
20. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
21. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomized trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996
22. Souhami RL, Spiro SG, Rudd RM, et al: Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
23. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
24. Kirschling RJ, Jung JH, Jett JR: A phase II trial of Taxol and G-CSF in previously untreated SCLC. Proc Am Soc Clin Oncol 13:326, 1994 (abstr 1076)
25. Latreille J, Cormier Y, Martins H, et al: Phase II trial of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13:343-345, 1996
26. Smyth JF, Bowman A, Smith I, et al: Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Eur J Cancer 29A:154, 1993 (suppl 6, abstr 849)
27. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058-1060, 1994
28. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285, 1994
29. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53:169-172, 1996
30. Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe C, et al: Phase II study of Vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993
31. Fujita A, Takabatake H, Tagaki S, et al: Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 22:889-893, 1995
32. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
33. Pujol JL, Le Chevalier T, Douillard JY, et al: CPT-11 (irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results). Eur J Cancer 31:821, 1995 (suppl 5)
34. Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
35. Miller AA, Lilenbaum RC, Lynch TJ, et al: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1965, 1996 (letter)
36. Takimoto CH, Arbuck SG: Clinical status and optimal use of topotecan. Oncology 11:1635-1646, 1997
37. Jett JR, Day R, Levitt M, et al: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 18:13, 1997 (suppl 1, abstr 38)
38. Hochster H, Speyer J, Wadler S, et al: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion: A NYGOG study. Ann Oncol 7:69, 1996 (abstr 326)